Area of research
Oncology · Hepatology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, and Gastrointestinal Tumor Research and Treatment.
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
Chinese expert consensus on refined diagnosis, treatment, and management of advanced primary liver cancer (2023 edition)
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Effect of different <scp>PD</scp>‐1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Development of a Sex-Specific Risk Scoring System for Predicting Cognitive Normal to Mild Cognitive Impairment (SRSS-CNMCI)
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology
Relationship Research between the Chinese Medicine Constitution and Sub-Health